APOA1 and amyotrophic lateral sclerosis: Additionally, proteomic analysis of CSF from ALS patients following autologous bone marrow-derived mesenchymal stem cell therapy revealed increased ApoA-I levels, raising questions about whether ApoA-I elevation in CSF reflects a compensatory response, disease progression, or an effect of the treatment itself [151].